131 related articles for article (PubMed ID: 2608022)
21. [Intrapleural administration of CDDP against malignant pleural effusions in breast cancer].
Kikuchi K; Tsuyuki A; Fujishiro Y; Utsumi T; Fujisaki M; Kurihara E; Uematsu M
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1905-8. PubMed ID: 2393307
[TBL] [Abstract][Full Text] [Related]
22. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
[TBL] [Abstract][Full Text] [Related]
23. Treatment of 121 patients with malignant effusion due to advanced lung cancer by intrapleural transfer of autologous or allogeneic LAK cells combined with rIL-2.
Liu X; Li D; Zhang C; Ba D; Liu J; Wan T; Li Z; Jin Y; He Y
Chin Med Sci J; 1993 Sep; 8(3):186-9. PubMed ID: 8142637
[TBL] [Abstract][Full Text] [Related]
24. [Clinical efficacy of LAK cell adoptive immunotherapy in advanced cancer patients].
Toge T; Takayama T; Kegoya Y; Kuninobu H; Yamaguchi Y; Hattori T
Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1455-8. PubMed ID: 2586438
[TBL] [Abstract][Full Text] [Related]
25. [The cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells].
Guo Y; Xing Z
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):80-2, 127. PubMed ID: 7553955
[TBL] [Abstract][Full Text] [Related]
26. [Adoptive immunotherapy of malignant pleural effusion with TIL/rIL2 (tumor-infiltrating lymphocytes/recombinant interleukin 2)].
Han B; Jia Y; Zhou M
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):91-3, 128. PubMed ID: 7553959
[TBL] [Abstract][Full Text] [Related]
27. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
28. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
Guo YS; Xing ZL
Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of pleural effusion caused by lung carcinoma with circular intrapleural hyperthermic perfusion and its mechanism].
Kang M; Zhou L; Lin P
Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1176-9. PubMed ID: 11769704
[TBL] [Abstract][Full Text] [Related]
30. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
31. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
Goey SH; Eggermont AM; Punt CJ; Slingerland R; Gratama JW; Oosterom R; Oskam R; Bolhuis RL; Stoter G
Br J Cancer; 1995 Nov; 72(5):1283-8. PubMed ID: 7577483
[TBL] [Abstract][Full Text] [Related]
32. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
Castagneto B; Zai S; Mutti L; Lazzaro A; Ridolfi R; Piccolini E; Ardizzoni A; Fumagalli L; Valsuani G; Botta M
Lung Cancer; 2001; 31(2-3):303-10. PubMed ID: 11165411
[TBL] [Abstract][Full Text] [Related]
33. [Impact of intrapleural hyperthermic perfusion on immunologic reaction state of cytokines TH1/TH2 of lung carcinoma patients with malignant pleural effusion].
Kang MQ; Cao YP; Deng F
Ai Zheng; 2008 Feb; 27(2):210-3. PubMed ID: 18279624
[TBL] [Abstract][Full Text] [Related]
34. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
35. Induction of murine lymphokine-activated killer cells by recombinant IL-7.
Lynch DH; Miller RE
J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262
[TBL] [Abstract][Full Text] [Related]
36. Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients.
Blanchard DK; Kavanagh JJ; Sinkovics JG; Cavanagh D; Hewitt SM; Djeu JY
Cancer Res; 1988 Nov; 48(22):6321-7. PubMed ID: 2972357
[TBL] [Abstract][Full Text] [Related]
37. [Locoregional adoptive immunotherapy using LAK cells and IL-2 against liver metastases from digestive tract cancer].
Ueda Y; Sonoyama T; Itoi H; Fujiwara H; Fuji N; Itoh T; Fujiki H; Yamashita T; Yoshimura T; Harada S; Okugawa K; Yamagishi H
Gan To Kagaku Ryoho; 2000 Oct; 27(12):1962-5. PubMed ID: 11086454
[TBL] [Abstract][Full Text] [Related]
38. [The clinical study of local treatment of ocular malignant tumors with IL-2 LAK cells].
Yang L; Zhang J; Liang G
Zhonghua Yan Ke Za Zhi; 1995 May; 31(3):215-7. PubMed ID: 7555407
[TBL] [Abstract][Full Text] [Related]
39. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome.
Yamaguchi Y; Hihara J; Hironaka K; Ohshita A; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hamai Y
Oncol Rep; 2006 Apr; 15(4):895-901. PubMed ID: 16525677
[TBL] [Abstract][Full Text] [Related]
40. Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion.
Takahashi K; Sone S; Kimura S; Ogura T; Monden Y
Chest; 1993 Jun; 103(6):1732-8. PubMed ID: 8404092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]